Henry Schein, Inc. (NASDAQ:HSIC) Shares Bought by Foyston Gordon & Payne Inc

Foyston Gordon & Payne Inc raised its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 1.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 145,846 shares of the company’s stock after acquiring an additional 1,744 shares during the quarter. Henry Schein makes up 2.3% of Foyston Gordon & Payne Inc’s portfolio, making the stock its 16th biggest holding. Foyston Gordon & Payne Inc owned approximately 0.11% of Henry Schein worth $9,349,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Summit Securities Group LLC acquired a new position in shares of Henry Schein in the second quarter worth $31,000. Beach Investment Counsel Inc. PA acquired a new position in shares of Henry Schein in the second quarter worth $37,000. Blue Trust Inc. raised its holdings in shares of Henry Schein by 104.2% in the second quarter. Blue Trust Inc. now owns 931 shares of the company’s stock worth $60,000 after acquiring an additional 475 shares during the last quarter. Mather Group LLC. raised its holdings in shares of Henry Schein by 16.8% in the second quarter. Mather Group LLC. now owns 1,502 shares of the company’s stock worth $96,000 after acquiring an additional 216 shares during the last quarter. Finally, Palisade Asset Management LLC acquired a new position in shares of Henry Schein in the first quarter worth $113,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Henry Schein Trading Down 0.4 %

Shares of HSIC opened at $70.55 on Friday. The company has a market capitalization of $8.94 billion, a P/E ratio of 23.83, a P/E/G ratio of 1.98 and a beta of 0.87. Henry Schein, Inc. has a one year low of $60.01 and a one year high of $82.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.90 and a current ratio of 1.55. The stock has a 50-day moving average price of $68.42 and a 200 day moving average price of $71.05.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.01. Henry Schein had a return on equity of 13.19% and a net margin of 2.82%. The firm had revenue of $3.10 billion during the quarter, compared to the consensus estimate of $3.27 billion. During the same quarter in the prior year, the business posted $1.31 earnings per share. Henry Schein’s revenue for the quarter was up .0% on a year-over-year basis. Sell-side analysts forecast that Henry Schein, Inc. will post 4.75 EPS for the current fiscal year.

Analyst Ratings Changes

HSIC has been the subject of several analyst reports. Evercore ISI dropped their target price on Henry Schein from $72.00 to $70.00 and set an “in-line” rating for the company in a research note on Wednesday, August 7th. Robert W. Baird lowered their price target on Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Barrington Research lowered their price target on Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Piper Sandler reaffirmed an “overweight” rating and issued a $86.00 target price on shares of Henry Schein in a research report on Friday, June 21st. Finally, UBS Group decreased their target price on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Henry Schein has an average rating of “Hold” and an average target price of $77.10.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.